IG
ACOR

ING Group’s Acorda Therapeutics ACOR Stock Holding History

ING Group’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-100
Closed -$457K – 702
2014
Q1 		$457K Hold
100
– – ﹤0.01% 614
2013
Q4 		$351K Hold
100
– – ﹤0.01% 612
2013
Q3 		$413K Hold
100
– – ﹤0.01% 626
2013
Q2 		$397K Buy
+100
New +$412K ﹤0.01% 610

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

ING Group's ACOR Position: Q2 2014 in Review

ING Group sold out of Acorda Therapeutics (ACOR) in Q2 2014, closing a stake of 100 shares — an estimated $457K sold.

ING Group first reported a position in ACOR in Q2 2013 and held it in 4 quarters. The position peaked at $457K in Q1 2014. 162 funds tracked by Wall St. Rank hold ACOR as of Q2 2014.

  • ING Group reported no remaining Acorda Therapeutics position as of Q2 2014 after selling out during the quarter.
  • ING Group sold 100 Acorda Therapeutics shares in Q2 2014, an estimated $457K.
  • ING Group first reported a position in Acorda Therapeutics in Q2 2013 and held it in 4 quarters.
  • ING Group's Acorda Therapeutics position peaked at $457K in Q1 2014.
  • 162 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2014.

Based on ING Group's 13F filing for Q2 2014, filed 14 Aug 2014.